CFDA Accepts CStone's IND Submission for PD-L1 Candidate

23:57 EDT 19 Oct 2016 | ChinaBio Today

CStone Pharma, a young Shanghai-Suzhou startup, reported that its application for clinical trials of a recombinant PD-L1 antibody was accepted for review by the CFDA. According to CStone, the candidate (WBP3155) is China's first innovative, fully humanized, full-length original format Immunoglobulin G (IgG) mAb candidate. WBP3155 was produced by the OMT platform, which suggests a connection with WuXi AppTec. WuXi in-licensed rights to the OMT platform for mAb discovery. In July, CStone raised $150 million in an A round from three China investors including WuXi Healthcare Ventures. More details....

Share this with colleagues:  

Original Article: CFDA Accepts CStone's IND Submission for PD-L1 Candidate


More From BioPortfolio on "CFDA Accepts CStone's IND Submission for PD-L1 Candidate"

Quick Search

Relevant Topics

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...

Recombinant DNA
Recombinant DNA is the formation of a novel DNA sequence by the formation of two DNA strands. These are taken from two different organisms. These recombinant DNA molecules can be made with recombinant DNA technology. The procedure is to cut the DNA of ...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...